New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus
An. bras. dermatol
; 90(3,supl.1): 165-167, May-June 2015. ilus
Article
in English
| LILACS
| ID: lil-755769
Responsible library:
BR1.1
ABSTRACT
Everolimus, a mammalian target of rapamycin inhibitor, is an emerging drug, which is being increasingly applied in oncology and solid organ transplantation. Oral ulcers are a frequent side effect associated with this immunosupressor. We report the case of a renal transplant recipient who developed disfiguring oral and perianal ulcers secondary to everolimus's toxicity. This is probably the first report of perianal involvement. Dermatologists need to be aware of the potential mucocutaneous adverse effects related to these new drugs that are becoming evermore common in our clinical practice.
.
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Anus Diseases
/
Skin Ulcer
/
Stomatitis
/
Kidney Transplantation
/
Everolimus
/
Immunosuppressive Agents
Limits:
Adult
/
Female
/
Humans
Language:
English
Journal:
An. bras. dermatol
Journal subject:
Dermatology
Year:
2015
Document type:
Article
Affiliation country:
Brazil
Institution/Affiliation country:
Universidade Federal de São Paulo/BR